mk 0663 has been researched along with cox 189 in 13 studies
| Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (cox 189) | Trials (cox 189) | Recent Studies (post-2010) (cox 189) |
|---|---|---|---|---|---|
| 549 | 173 | 265 | 163 | 49 | 47 |
| Protein | Taxonomy | mk 0663 (IC50) | cox 189 (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 0.007 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.076 | |
| Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.04 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Frölich, JC; Stichtenoth, DO | 1 |
| Hochberg, MC | 1 |
| Geisslinger, G; Manderscheid, C; Niederberger, E | 1 |
| Ashcroft, DM; Chen, LC | 1 |
| Baraf, HS | 1 |
| Hunt, RH; Yuan, Y | 1 |
| Klotz, U; Shi, S | 1 |
| Elliott, WJ | 1 |
| Honjo, H; Iwamoto, K; Uwai, Y | 1 |
| Angioni, C; Felden, L; Ferreiros, N; Geisslinger, G; Lötsch, J; Schreiber, Y; von Hentig, N; Walter, C | 1 |
| Hu, RW; Li, HY; Li, JS; Miao, XP; Ouyang, Q; Zhang, Y | 1 |
| Hansen, SH; Skonberg, C; Syed, M | 1 |
8 review(s) available for mk 0663 and cox 189
| Article | Year |
|---|---|
The second generation of COX-2 inhibitors: what advantages do the newest offer?
Topics: Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Drug Interactions; Etoricoxib; Humans; Isoenzymes; Isoxazoles; Membrane Proteins; Organic Chemicals; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfonamides; Sulfones | 2003 |
COX-2 selective inhibitors in the treatment of arthritis: a rheumatologist perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Membrane Proteins; Organic Chemicals; Osteoarthritis; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Rheumatology; Sulfonamides; Sulfones; Treatment Outcome | 2005 |
Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Etoricoxib; Humans; Isoxazoles; Lactones; Models, Statistical; Myocardial Infarction; Naproxen; Odds Ratio; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Risk; Risk Factors; Sulfonamides; Sulfones | 2007 |
Efficacy of the newest COX-2 selective inhibitors in rheumatic disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Arthritis, Rheumatoid; Cardiovascular Diseases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Gastrointestinal Hemorrhage; Humans; Membrane Proteins; Osteoarthritis; Patient Selection; Pyridines; Rheumatic Diseases; Risk Assessment; Risk Factors; Spondylitis, Ankylosing; Sulfones | 2007 |
Global gastrointestinal safety profile of etoricoxib and lumiracoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Interactions; Endoscopy, Gastrointestinal; Etoricoxib; Humans; Occult Blood; Patient Selection; Peptic Ulcer; Peptic Ulcer Hemorrhage; Pyridines; Risk Assessment; Risk Factors; Sulfones | 2007 |
Clinical use and pharmacological properties of selective COX-2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Drug Monitoring; Etoricoxib; Humans; Osteoarthritis; Pain; Pyrazoles; Pyridines; Sulfonamides; Sulfones | 2008 |
Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Hypertension; Isoxazoles; Lactones; Pyrazoles; Pyridines; Risk; Risk Factors; Sulfonamides; Sulfones | 2010 |
Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Colitis, Ulcerative; Crohn Disease; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Humans; Isoxazoles; Lactones; Pyrazoles; Pyridines; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Sulfonamides; Sulfones | 2014 |
1 trial(s) available for mk 0663 and cox 189
| Article | Year |
|---|---|
Similar maximum systemic but not local cyclooxygenase-2 inhibition by 50 mg lumiracoxib and 90 mg etoricoxib: a randomized controlled trial in healthy subjects.
Topics: Adult; Arachidonic Acid; Cross-Over Studies; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Diclofenac; Double-Blind Method; Etoricoxib; Humans; Male; Prostaglandins; Pyridines; Sulfones; Young Adult | 2014 |
4 other study(ies) available for mk 0663 and cox 189
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib.
Topics: Animals; Cell Nucleus; Cell Proliferation; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Etoricoxib; Gene Expression Regulation; Macrophages; Mice; NF-kappa B; Nitric Oxide Synthase Type II; Nitrites; Organic Chemicals; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Pyridines; Sulfones; Transcription Factor AP-1 | 2006 |
Inhibitory effect of selective cyclooxygenase-2 inhibitor lumiracoxib on human organic anion transporters hOAT1 and hOAT3.
Topics: Animals; Binding, Competitive; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Dose-Response Relationship, Drug; Estrone; Etoricoxib; Humans; Inhibitory Concentration 50; Isoxazoles; Kinetics; Lactones; Methotrexate; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; p-Aminohippuric Acid; Pyrazoles; Pyridines; RNA, Complementary; Sulfonamides; Sulfones; Xenopus laevis | 2010 |
Mitochondrial toxicity of selective COX-2 inhibitors via inhibition of oxidative phosphorylation (ATP synthesis) in rat liver mitochondria.
Topics: Adenosine Triphosphate; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Diclofenac; Etoricoxib; Isoxazoles; Lactones; Male; Mitochondria, Liver; Oxidative Phosphorylation; Pyridines; Rats, Sprague-Dawley; Sulfonamides; Sulfones | 2016 |